Join to access to all OVN content. Join for Free
3 KEY Factors that Altered the MSL Role Since 2020
MSL role evolution virtual engagement strategic thinkers AI in medical affairs post-COVID hiring practices

3 KEY Factors that Altered the MSL Role Since 2020


Share This Article


Summary

Join Mitchell D’Rozario and Tom Caravela as they celebrate the podcast's 3-year anniversary by exploring three key factors transforming the MSL role since 2020. They discuss the shift to virtual engagement, the evolution of MSLs from scientific messengers to strategic thinkers, and the integration of AI technologies like ChatGPT in medical affairs. The episode also reflects on insights from past guests, evolving hiring practices post-COVID-19, and the growing influx of clinicians into MSL positions. Tune in for predictions on future trends in the MSL landscape.

This episode features Mitchell D’Rozario, Sr Medical Science Liaison at Genentech discusses 3 ways the MSL role has changed since March of 2020
We discuss….

👉 What was the “silver lining” from COVID
👉 How virtual engagement has emerged and what MSLs can do better
👉 Why MSLs are the “curators of knowledge” and “oracles of information”
👉 The importance of authenticity
👉 What’s next for the MSL role

Click for Source
MSL role evolution, virtual engagement, strategic thinkers, AI in medical affairs, post-COVID hiring practices

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Empowering people to drive medical affairs performance with AI
Partner Avatar Envision Pharma Group

Empowering people to drive medical affairs performance with AI

Podcast
How Medical Affairs Professionals Should Engage with Digital Opinion Leaders
Partner Avatar MSL Talk: Tom Caravela, Paul Ward

How Medical Affairs Professionals Should Engage with Digital Opinion Leaders

Podcast
Fierce Pharma Engage 2025 - RECAP
Partner Avatar MSL Talk: Tom Caravela, Patrina Pellett

Fierce Pharma Engage 2025 - RECAP

Article
Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale
OVN Avatar S.F. Oosting, J. Barriuso, A. Bottomley, M. Galotti, B. Gyawali, B. Kiesewetter, N.J. Latino, F. Martinelli, M. Pe, G. Pentheroudakis, F. Roitberg, H. Vachon, E.G.E. de Vries, M. Piccart, N.I. Cherny

Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale

Article
Sponsorship of oncology clinical trials in the United States according to age of eligibility
OVN Avatar Dylan V Neel, David S Shulman, Clement Ma, Florence Bourgeois, Steven G DuBois

Sponsorship of oncology clinical trials in the United States according to age of eligibility

Article
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
OVN Avatar Michael Z. Liao, Dan Lu, Matts Kågedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li

Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?

Explore OVN